Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Cancer Hospital & Institute
About this trial
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged ≥18 years old; ECOG 0 or 1;
Patients with HER2 positive or low tumors;
Receives neoadjuvant therapy
Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
Disqualifiers
Significant hepatic or renal dysfunction;
Is pregnant or ready to pregnant;
Cannot keep their states for half an hour;
Refused to join the clinical research;
Trial design
Design model
Single group
Treatments tested in this trial
HER2 expression of PET imaging
RadiationEvaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast patients treated with ADC therapy
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: HER2 expression of PET imagingExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Changes in SUVmax before and after treatment
The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value (SUV) on PET/CT
Time frame
Before treatment, 9 weeks after treatment, before surgerySponsors and contacts
Click on the lead sponsor to view all of their trials.
Peking University Cancer Hospital & Institute
Lead sponsor
The Affiliated Hospital of Qingdao University
Collaborator
North Sichuan Medical College
Collaborator
Source ClinicalTrials.gov